China Patient Support Program Market Analysis - Insights10.pdf

In 2022, the market was valued at $3.89 Bn, and it’s set to soar to an impressive $15.71 Bn by 2030, with a remarkable CAGR of 19.1%. This rapid growth highlights the increasing importance of patient-centric care and support programs in the Chinese healthcare landscape. Join the conversation and see how these industry giants are shaping the future of patient care in China!

1. CHINA PATIENT
SUPPORT
PROGRAM

2. HOW PSPs IN CHINA WORK?
Charitable organizations are
central to PSPs, ensuring effective
aid through several key roles:
Program Management: Designing,
planning, and operating PSPs.
Fundraising and Advocacy:
Securing donations and promoting
PSPs for public and governmental
support
Patient Support: Assessing
eligibility, educating the public,
coordinating with healthcare
providers, and ensuring safe
medication distribution
Under Article 20 of the "Measures
for the Supervision and
Administration of Drug
Circulation," pharmaceutical
companies are prohibited from
engaging in bundled sales or
giving away prescription and Class
A OTC drugs
Therefore, to support Patient
Support Programs (PSPs) by
providing free drugs and funds,
these companies must partner with
recognized charities, making these
charities crucial to the operation of
PSPs
PSPs by charitable organizations
provide vital support for patients
with serious illnesses through
various models:
Co-assistance Model: Patients
initially pay for a treatment cycle
and then receive subsequent
cycles free.
Full Free Model: Patients receive
drugs at no cost without any self-
payment or treatment
requirements
Financial Assistance Model: Offers
cash rebates based on drug
purchase invoices to help cover
treatment expenses
Pharmaceutical
Companies
Charitable
Organization
Patients

3. 2022 2023F 2024F 2025F 2026F 2027F 2028F 2029F 2030F
0
5
10
15
20
China Patient Support
Program Market Analysis in
2022 was sized at $3.89 Bn
and is projected to reach
$15.71 Bn by 2030,
exhibiting a CAGR of 19.1%
during the forecast period
China Patient Support Program Market Forecast,
2022-2030F (in $Bn)
MARKET SIZE &
FORECAST
CAGR-19.1%
3.89
4.63
5.51
6.56
7.81
9.3
11.08
15.71
13.19

4. Top Pharma Companies Top Charitable Organizations
TOP PLAYERS IN CHINA

5. MARKET SEGMENTATION
Drug assistance1.
Financial assistance2.
In,
82%
2022
of all PSPs, marking the highest proportion among
drug assistance programs accounted for
the various types of program
Tumors1.
Rare disease2.
Chronic disease3.
Autoimmune disease4.
Other5.
First tier cities1.
New first tier cities2.
Second tier cities3.
Third tier cities4.
Fourth tier cities5.
Fifth tier cities6.
BY TYPE BY DISEASE BY CITIES

6. MARKET DRIVER & RESTRAINT
MARKET DRIVERS: MARKET RESTRAINTS:
An aging population creates a
booming demand for PSPs
Lack of awareness about the disease &
PSPs challenges their adoption in China
Digital health adoption in China
creates opportunities for PSPs
Lack of standardization hinders patient
choice in China's booming PSPs market
High support from the government and
increasing donations drive growth